Table 1.
Baseline characteristics for the 109 VoxTox participants. Prescribed dose to the prostate was 74 Gy in 37 fractions over 7.5 weeks. All patients were treated with androgen deprivation therapy. IBD = inflammatory bowel disease, IQR = interquartile range, PSA = prostate-specific antigen, SD = standard deviation.
| Clinical data for VoxTox patients (n = 109) | |
|---|---|
| Age, years | |
| Median (IQR) | 68 (64–71) |
| Range | 51–80 |
| T stage,n(%) | |
| T1A/T1B/T1C/T1X | 24 (22%) |
| T2A/T2B/T2C/T2X | 34 (31%) |
| T3A/T3B/T3X | 45 (41%) |
| T4 | 0 |
| Not known | 6 (6%) |
| Gleason score,n(%) | |
| 6 | 23 (21%) |
| 7 | 44 (40%) |
| ⩾8 | 39 (36%) |
| Not known | 3 (3%) |
| PSA (ng/ml) | |
| Median (IQR) | 11 (7–20) |
| Mean (SD) | 20 (30) |
| Not known | 3 (3%) |
| Clinical history | |
| Diabetes | 10 (9%) |
| Hypertension | 35 (32%) |
| IBD or diverticular disease | 7 (6%) |
| Previous pelvic surgery | 7 (6%) |
| Haemorrhoids past 12 months | 3 (3%) |
| Any previous TURP | 9 (8%) |
| Not known | 9 (8%) |